Post Marketing Study on Pluvicto in Korea
A Post Marketing Surveillance on PluvictoTM (Lutetium(177Lu) Vipivotide Tetraxetan) in South Korea; An Open-label, Non-interventional, Primary Data Collection, Multi-center, Non-comparative, Non-randomized Observational Study to Assess Safety and Effectiveness of Pluvicto in Real World Setting
About This Trial
- This study is for adult men in South Korea who are already receiving or scheduled to receive the approved prostate cancer drug Pluvicto.
- Researchers are collecting real-world information to better understand how safely and effectively the treatment works in routine medical care.
- Because this is an observational study, taking part will not change your planned medical treatment.
- If you choose to join, you will simply give permission for the research team to review your health records during your care.
More Information
- Post marketing study on Pluvicto in Korea
Who Can Enroll
- Age Range: 18 - 100 years
- Gender: Male
- Who This Trial is For: This study is for adult men in South Korea who are already receiving or scheduled to receive the approved prostate cancer drug Pluvicto.
Study Details
- Start Date: April 18, 2025
- Lead Sponsor: Novartis Pharmaceuticals
Full Eligibility Criteria
Inclusion Criteria
Study participants eligible for inclusion in this study must meet all of the following
criteria:
- Male adult patient age ≥ 18
- Subject who are being treated with Pluvicto or whose treatment plan is finalized and scheduled to be administered at the time of consent by physician in accordance with the approved indication in South Korea
- Subject who provided the written informed consent prior to the study enrollment
Exclusion Criteria
Study participants meeting any of the following criteria are not eligible for inclusion
in this study:
- Subject whose medical record is not accessible
- Subject who is not willing to provide the informed consent
Treatments
- Other: Lutetium vipivotide tetraxetan